...
首页> 外文期刊>Journal of Bangladesh Society of Physiologist >Large airway ventilatory functions in female patients of rheumatoid arthritis with methotrexate therapy- is there any change?
【24h】

Large airway ventilatory functions in female patients of rheumatoid arthritis with methotrexate therapy- is there any change?

机译:大型气道通气功能在女性风湿性关节炎患者中具有甲氨蝶呤治疗 - 有没有变化?

获取原文
           

摘要

Background: Methotrexate (MTX) is widely used in the treatment of Rheumatoid arthritis (RA) as first line disease modifying anti-rheumatoid drug. Low dose MTX may reduce lung function status in RA patients. Objective: To observe the changes in large airway ventilatory variables in RA patients after MTX therapy. Methods: For this prospective observational study, 24 female RA patients of age ranges between 15 to 65 years were selected from the Out-Patient Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Age and BMI matched 24 apparently healthy females were also selected Control. To assess the large airway ventilatory function, FVC, FEV 1 , FEV1/ FVC% and PEFR of all subjects were measured with a portable digital Spirometer, PONY FX (Cosmed, Italy) at Day 0. In addition, all these variables were again measured in the RA patients after 180 days of MTX therapy. For statistical analysis, independent sample t test and paired sample t test were performed. Results: All the study variables (except FEV 1 /FVC%) were significantly (p&0.001) lower in RA groups at day 0 as well as at day 180, compared to healthy controls. Again all these variables were almost similar in the RA patients at day 180 when compared to those of day 0. Conclusion: Large airway ventilatory function deteriorated in RA patients, which may not be recovered by six months methotraxate therapy. J Bangladesh Soc Physiol. 2018, June; 13(1): 35-40.
机译:背景:甲氨蝶呤(MTX)广泛用于治疗类风湿性关节炎(RA)作为修饰抗类风湿药物的第一线疾病。低剂量MTX可以降低RA患者的肺功能状态。目的:观察MTX治疗后RA患者大型气道通气变量的变化。方法:对于这项前瞻性观察研究,24例雌性RA患者在15至65岁之间,选自达卡州Bangabandhu Sheikh Mujib医科大学Vieumatology,达卡,达卡。年龄和BMI匹配的24个明显健康的女性也被选择控制。为了评估大型气道通气功能,所有受试者的FVC,FEV 1,FEV1 / FVC%和PEFR都是通过便携式数字肺部计,第0天的PONY FX(COSMED,意大利)测量所有受试者的PONE 0.此外,再次测量所有这些变量在RA患者的MTX治疗后180天后。对于统计分析,进行独立的样品T测试和配对样品T试验。结果:与健康对照相比,所有研究变量(FEV 1 / FVC%除外)显着(P <0.001)在第0天以及第180天,在第180天,与健康对照相比。与第180天相比,所有这些变量在第180天时,所有这些变量几乎相似。结论:RA患者中的大型气道通气功能恶化,甲氨蝶呤治疗可能不会被六个月恢复。 J孟加拉国Soc Physiol。 2018年6月; 13(1):35-40。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号